Corcept Therapeutics

Bragar Eagel & Squire, P.C. Is Investigating Medallion, RBB, Agrify, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
星期三, 九月 7, 2022
CEO, RBB, Therapy, NASDAQ, Royal Business Bank, HIPAA, Accountability Act, Sale, Health Insurance Portability and Accountability Act, EVP, CORT, SEC, HuffPost, U.S. Securities and Exchange Commission, District, GLOBE, Company, News, Corcept Therapeutics, Alpha, Record, Medal, Online gambling, Animal, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Medallion, RBB, Agrify, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
星期四, 九月 1, 2022
CEO, RBB, Therapy, NASDAQ, Royal Business Bank, HIPAA, Accountability Act, Sale, Health Insurance Portability and Accountability Act, EVP, CORT, SEC, HuffPost, U.S. Securities and Exchange Commission, District, GLOBE, Company, News, Corcept Therapeutics, Alpha, Record, Medal, Online gambling, Animal, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Medallion, RBB, Agrify, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
星期六, 八月 27, 2022
CEO, RBB, Therapy, NASDAQ, Royal Business Bank, HIPAA, Accountability Act, Sale, Health Insurance Portability and Accountability Act, EVP, CORT, SEC, HuffPost, U.S. Securities and Exchange Commission, District, GLOBE, Company, News, Corcept Therapeutics, Alpha, Record, Medal, Online gambling, Animal, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Medallion, RBB, Agrify, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
星期一, 八月 22, 2022
CEO, RBB, Therapy, NASDAQ, Royal Business Bank, HIPAA, Accountability Act, Sale, Health Insurance Portability and Accountability Act, EVP, CORT, SEC, HuffPost, U.S. Securities and Exchange Commission, District, GLOBE, Company, News, Corcept Therapeutics, Alpha, Record, Medal, Online gambling, Animal, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Medallion, RBB, Agrify, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
星期二, 八月 16, 2022
U.S. Securities and Exchange Commission, Alpha, Medal, CEO, CORT, GLOBE, Corcept Therapeutics, SEC, Sale, District, Accountability Act, Health Insurance Portability and Accountability Act, Therapy, Company, EVP, NASDAQ, HIPAA, News, Record, RBB, HuffPost, Royal Business Bank, Online gambling, Animal, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Medallion, RBB, Agrify, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
星期四, 八月 11, 2022
U.S. Securities and Exchange Commission, Alpha, Medal, CEO, CORT, GLOBE, Corcept Therapeutics, SEC, Sale, District, Accountability Act, Health Insurance Portability and Accountability Act, Therapy, Company, EVP, NASDAQ, HIPAA, News, Record, RBB, HuffPost, Royal Business Bank, Online gambling, Animal, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Hannon Armstrong, NIO, and Generac and Encourages Investors to Contact the Firm

Retrieved on: 
星期六, 八月 6, 2022
Muddy Waters Research, P.C, U.S. Securities and Exchange Commission, HASI, CORT, NYSE, GLOBE, NIO, Corcept Therapeutics, Sale, Holding, District, Securitization, Income, Accountability Act, Health Insurance Portability and Accountability Act, Therapy, Company, Acquisition, Holding Foreign Companies Accountable Act, Generac Holdings, Partnership, Hong Kong Stock Exchange, NASDAQ, GAAP, HIPAA, Research, News, Record, FTC, Solution, Annual report, ADR, Online gambling, Audit, Security (finance)

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Corcepts stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.
  • For more information on the Generac investigation go to: https://bespc.com/cases/GNRC
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
星期三, 八月 3, 2022
Intellectual property, ALS, Corcept Therapeutics, Goal, GRACE, PIN, COVID-19, NASH, Depression, Neck, Fatigue, Anxiety, Investor, Woman, Microdeletion syndrome, Patient, NASDAQ, Irritability, Weight gain, Chicago (franchise), Food, Diabetes, CORT, NDA, Energy drink, United, Cushing's syndrome, Progression-free survival, Safety, Prostate cancer, Disease, Enrollment, Muscle, Insurance, Investment, Life expectancy, Doctor of Pharmacy, Intention, GLOBE, Income, MD, Liver disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ageing, University, Traffic barrier, SEC, Population, Pharmaceutical industry, Video game

Diluted net income per common share of $0.24, compared to $0.21 in second quarter 2021

Key Points: 
  • Diluted net income per common share of $0.24, compared to $0.21 in second quarter 2021
    Cash and investments of $382.0 million, compared to $368.1 million at March 31, 2022
    Corcepts second quarter 2022 revenue was $103.4 million, compared to $91.6 million in the second quarter of 2021.
  • Second quarter operating expenses were $72.0 million, compared to $59.6 million in the second quarter of 2021, due to increased clinical trial activity, expenses to support the expansion of our clinical development and commercial teams and legal fees.
  • Net income was $27.4 million in the second quarter of 2022, compared to $26.5 million in the second quarter of 2021.
  • Cash and investments increased $13.9 million in the second quarter, to $382.0 million at June 30, 2022.

Bragar Eagel & Squire, P.C. Is Investigating Carvana, Corcept, Cassava, and Hannon Armstrong and Encourages Investors to Contact the Firm

Retrieved on: 
星期一, 八月 1, 2022
Sale, Experiment, GLOBE, Health Insurance Portability and Accountability Act, Research, HIPAA, U.S. Securities and Exchange Commission, Securitization, PLOS One, NYSE, Muddy Waters Research, CORT, The New York Times, Cassava, Income, Corcept Therapeutics, Accountability Act, NASDAQ, GAAP, News, Company, Carvana, Record, District, HASI, Online gambling, Renewable energy, Audit, Security (finance), P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Carvanas stock price fell $6.55 per share, or 15.75%, to close at $35.05 per share on May 18, 2022.
  • For more information on the Hannon Armstrong investigation go to: https://bespc.com/cases/HASI
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Retrieved on: 
星期三, 七月 27, 2022
NASDAQ, Liver disease, PIN, CORT, GLOBE, Patient, Weight gain, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Corcept Therapeutics, Food, Pharmaceutical industry

MENLO PARK, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 3, 2022.

Key Points: 
  • MENLO PARK, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 3, 2022.
  • The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
  • Participants must register in advance of the conference call by clicking here .
  • Upon registering, each participant will receive a dial-in number, and a unique access PIN.